RNA Therapeutics 2022 Virtual Conference

Bolstering The Latest Advances and Opportunities in RNA-Based Medicine

Conference Proceedings

Standard Price

US$ 616.05

Change your currency: USD EUR GBP

User Details

We are proud to announce the 13th Annual RNA Therapeutics Conference taking place on 9 - 10 February 2022

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.

The RNA therapeutics industry has grown at an exponential rate in recent years, with an increased spotlight following the industry's leading role in developing vaccines against COVID-19 in response to the global pandemic. This year's conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development. Furthermore, the 2022 agenda will explore innovations in novel and targeted delivery, RNAi innovations and antisense oligonucleotide therapeutics. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of RNA with case studies on the treatment of cardiovascular disease, neurological diseases and oncology.

Join us in February 2022, as our 13th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments of the industry.

Benefits of Attending

  • Explore how mRNA vaccines have led the way in the response against COVID-19 and key takeaways for the industry
  • Understand the potential of RNAi and antisense oligonucleotides for the treatment of  cardiovascular and neurological diseases
  • Delve into the latest innovations in novel RNA delivery and target specificity
  • Engage in the growing advances and development of RNA tools for vaccines and anti-infectives

Who should attend

Key Job Titles include:
  • Research & Development Directors/Managers/Scientists
  • Heads of Clinical Development
  • Heads of Pre-Clinical Development
  • Head of RNA Biology
  • Head of RNA Formulation and Drug Delivery
  • Head of Pre-clinical R&D
  • Head of New Modalities
  • Head of Discovery
  • Senior Scientists
  • Chief Scientific Officers
  • Chief Medical Officers


  • Alfica Sehgal, VP Head of Discovery, CAMP4 Therapeutics
  • Arun Kumar, Preclinical Vaccine Development Lead, Coalition for Epidemic Preparedness Innovations (CEPI)
  • Cristina R. Reschke, Lecturer, Royal College of Surgeons in Ireland
  • David Lowe, Vice President, Evox Therapeutics Ltd
  • Dong Ki Lee, CEO, OilX Pharmaceuticals
  • Eric Lim, Associate Director, Bioinformatics, Stoke Therapeutics, Inc
  • Gareth Morris, ERUK Emerging Leader Research Fellow, University College London
  • Gayatri Arun, Vice President of Biology, Envisagenics Inc
  • Heinrich Haas, Vice President Formulation and Drug Delivery, BioNTech RNA Pharmaceuticals
  • Jimmy Weterings, Principal Scientist, AstraZeneca
  • Kirsty Wydenbach, Deputy Unit Manager/Senior Medical Assessor, MHRA
  • Kyeongmi Kim, Principal Scientist, mCureX Therapeutics
  • Martin Akerman, CTO & Co-Founder, Envisagenics
  • Michael T. Migawa, Executive Director, Ionis Pharmaceuticals Inc.
  • Michel Janicot, Chief Development Officer, InteRNA Technologies BV
  • Nagy Habib, Head of HBP Surgery, Co-Founder, Imperial College London and MiNA Therapeutics
  • Punit Seth, Vice President, Ioinis Pharma
  • Rea Lardelli, Senior Scientist, Locanabio
  • Rok Sekirnik, Head of Process Development, mRNA pDNA, BIA Separations d.o.o
  • Samir Ounzain, CEO, HAYA Therapeutics
  • Steve Pascolo, Founder and CEO, Miescher Pharma GmbH
  • Sudhir Agrawal, Founder and President, ARNAY Sciences
  • Tamar Grossman, Global Head of RNA and Targeted Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson
  • Thomas Thum, Founder and Chief Scientific Officer, Cardior Pharmaceuticals
  • Volker Germaschewski, Senior Vice President of Research & Development, eTheRNA Immunotherapies NV

Please fill in your name and email to receive the Virtual Conference Agenda of this event.


The venue is not yet available for this event.
Follow this event to be informed when the venue is available and stay informed on other changes.

Event details
Organizer :SAE Media Group
Event type :Conference
Attendance :Online Event
Reference :ASDE-23200

Other interesting Biomarker / Molecular Diagnostics / Enzymes events